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Abstract 
The delivery of drugs and active agents to the skin by formulations containing 
nanoparticles is a topic of considerable current interest. A number of studies have shown 
important advantages of these nanostructure-based delivery systems over conventional 
formulations. This review describes the composition, preparation, and characteristics of a 
wide range of novel vectors, including nanoemulsions, liposomes, transfersomes, solid lipid 
nanoparticles, polymeric nanoparticles, ethosomes and niosomes.  
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1 Introduction 
The skin is the largest organ in the human body by weight, contributing about 10% of total 
weight, and covering an average area of 1.7 m2. It regulates water and heat loss, and prevents 
the invasion of noxious chemicals and microorganisms. Because skin is an easily accessible 
organ, its potential as an alternative route for administering drugs for both systemic and local 
effect has attracted considerable interest [1]. Equally, a large segment of the cosmetic industry 
is focused on the delivery of “actives” to and into the skin. However, molecules do not easily 
penetrate the skin because of its excellent barrier function. As a result, various nano-carriers 
have been developed in an attempt to reversibly modulate the skin barrier and/or to provide 
novel delivery systems for the active of interest. These particulate carriers include 
nanoemulsions, liposomes, transfersomes, solid lipid nanoparticles, polymeric nanoparticles, 
ethosomes and niosomes. A schematic representation of their structures is shown in Figure 1.  
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2 Skin 
2.1 The structure of the skin 
The skin consists of the epidermis and the dermis, which sits on a layer of subcutaneous 
fat.  
The epidermis contains four histologically distinct layers, from the innermost stratum 
basale via the stratum spinosum and stratum granulosum (SG) to the superficial stratum 
corneum (SC). The SC has been represented as a “brick and mortar” structure [2] in which the 
corneocytes are embedded in an intercellular lipid matrix. The corneocytes comprise insoluble 
keratins enveloped by cross-linked proteins, and are arranged in parallel, overlapping, 
multicellular stacks perpendicular to the skin surface [1]. The inter-corneocyte space is filled 
with lipids, usually present in the crystalline phase [3]. Most SC lipids are synthesized in the 
viable epidermis during differentiation [4], they are released into the intercellular spaces at the 
SG-SC interface from lamellar bodies. The major SC lipids are ceramides, fatty acids and 
cholesterol. Eight classes of ceramides have been identified. The lipids are arranged in 
multiple bilayers with a periodicity of about 13 nm. Unlike almost all other membranes in the 
body, the SC does not contain phospholipid [2]. This “brick and mortar” structure is now 
accepted as the location of the skin’s excellent permeability barrier, and the SC is the 
rate-limiting barrier to the transcutaneous penetration and absorption of most chemicals 
following topical administration [5].   
There are three possible pathways of molecular penetration across the SC: (i) intercellular 
via the lipids between the corneocytes; (ii) transcellular crossing through the corneocytes and 
the surrounding lipids; (iii) appendagal via follicles and sweat ducts (Figure 2) [6]. The 
principal route is generally believed to be intercellular. The principal route is generally 
believed to be intercellular, although the appendageal route, in particular that encompassing 
the hair follicle and associated sebaceous gland, is also important in certain circumstances 
[7-12] and may offer an opportunity for drug targeting in the treatment of hair loss or acne, 
for example [13-16]. Some permeation enhancers (e.g., oleic acid) and vesicular carriers are 
thought to disorder the SC lipids and facilitate transport across the skin [17-19].  
Underlying the SC is the viable epidermis, the thickness of which is typically ~100 µm, 
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ranging from as little as 50 µm to around 800 µm on the load-bearing palms and soles of the 
feet [1]. The principal cells of the viable epidermis are keratinocytes, but there are also 
melanocytes, Langerhans cells, migrant macrophages and lymphocytes [20]. However, there 
are no blood vessels in the epidermis.  
The dermis is typically 3–5 mm thick and is the major component of human skin. It is rich 
in blood vessels, lymphatic vessels and nerve endings. The skin appendages, which include 
hair follicles, sebaceous glands and sweat glands, also originate in the dermis. This layer 
resembles an aqueous gel and is a minimal barrier to drug transport. As mentioned above, the 
hair follicles and associated sebaceous glands are considered to play a role with respect to 
transport across the skin; given that sebum consists mostly of neutral, non-polar lipids, it may 
be anticipated that this route favours more lipophilic permeants.  
The subcutaneous fat layer bridges between the dermis to the underlying tissue, and plays 
a negligible role in the percutaneous absorption of topically applied substances.  
 
2.2 Techniques to evaluate nanoparticle disposition on and within the skin 
To evaluate nanoparticle penetration disposition on/ and/or within the skin, several 
methods have been employed, including Franz-type diffusion cell experiments, differential 
tape-stripping of the stratum corneum [21,22], laser scanning confocal microscopy (LSCM) 
[23-27], multi-photon fluorescence microscopy (MFM) [28], and transmission electron 
microscopy (TEM) [29].  These techniques have permitted qualitative and semi-quantitative 
deductions about the extent and mechanisms of nanoparticle uptake into the stratum corneum 
to be deduced. 
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3 Nanoemulsions 
3.1 Composition and preparation 
Nanoemulsions are stable dispersions with mean droplet diameters of a few hundred 
nanometers, and are sometimes called sub-micron or mini-emulsions. These systems are 
composed of oil, water, and one or more surface-active agents, and may be oil-in-water (o/w) 
or water-in-oil (w/o) dispersions [30]. In some circumstances, nanoemulsions may be formed 
using phospholipids as one of the surface-active constituents; if the level of lipid is high, the 
concurrent formulation of liposomes is possible [31]. The aqueous phase may contain 
hydrophilic, pharmaceutical or cosmetic active ingredients and preservatives, while the oil 
phase is typically composed of mineral oil, silicone oil, vegetable oil, esters of fatty acids, 
and/or lipophilic active ingredients. Surfactants, such as disodium stearoyl glutamate, sucrose 
alkyl ester, sorbitan alkyl ester and dimethicone copolyol, are added to the formulation to 
allow formation of a stable dispersion and guarantee an appropriate shelf life of the product.  
Both o/w and w/o nanoemulsions can be used in pharmaceutical preparations for topical 
administration. In the former case, the common oil core constituents are triglycerides, 
propylene glycol mono caprylic ester, cholesteryl esters and cholesterol [32]. Most 
nanoemulsions in cosmetics are oil-in-water and contain 10-20% oil stabilized with 0.5-2% 
emulsifying agent. Popular oils are triglycerides, silicones, isopropyl myristate, isocetyl 
isostearate and isododecane. As well as conventional surfactants, polymeric emulsifiers, such 
as carbomers and hydroxypropyl methylcellulose (HPMC), are also being used to produce 
stable products with a pleasant appearance [33, 34]. Carbomers are crosslinked polyacrylic 
acid polymers; and represent the most widely used thickening agents in skincare products [35]. 
Once introduced into a nanoemulsion, irregular structures on the order of a micron in size are 
observed (Figure 3), in proportion to the amount of carbomer employed. Carbomers can form 
a thick protective gel layer around each oil droplet and increase the viscosity of the external 
phase. Following contact with the skin, electrolytes from the skin surface cause the protective 
gel layer to deswell instantly. The oil phase is released and a thin film is deposited on the skin. 
This mechanism permits the convenient formulation of sun-care products which are 
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ultimately waterproof despite their predominantly hydrophilic properties prior to application. 
The emulsification mechanism of HPMC is similar to that of carbomer, although the former is 
less sensitive to the presence of electrolytes. It is believed that the mechanical stress, imparted 
on application of these emulsions, causes a partial breakdown of their structures such that a 
thin film of oil spreads over the skin surface, reducing its wettability. After the water has 
evaporated, a flexible film remains consisting of oil droplets embedded into the polymer 
matrix [33].  
Nanoemulsions are easily produced in large quantities by mixing a water-immiscible oil 
phase into an aqueous phase using a high-stress, mechanical extrusion process [36, 37].  
3.2 Applications of nanoemulsions in pharmaceutics 
An o/w nanoemulsion containing 10% (m/m) oil (propylene glycol mono-caprylic ester 
and glycerol triacetate), 50% (m/m) surfactant (diethylene glycol monoethyl ether and 
Tween-80) and 40% (m/m) water has been suggested as a vehicle for the improved 
transdermal delivery of celecoxib [38]. In vitro skin permeation studies showed enhanced 
percutaneous uptake of the drug from the nanoemulsion relative to a simple gel [38]. In vivo, 
inhibition of carrageenan-induced paw edema in rats was observed when celecoxib 
nanoemulsion was used. The ability of nanoemulsion formulations to enhance topical drug 
delivery has also been shown for ketoprofen [39]. It was claimed that the drug permeation 
rate could be manipulated by changing the relative amounts of oil, surfactants and 
co-surfactants. Similarly, another study with an aceclofenac nanoemulsion showed improved 
permeation of the drug into rat abdominal skin, and significantly increased anti-inflammatory 
effect on carrageenan-induced paw edema in rats in vivo, when compared with a gel 
formulation [40].   
As well as acting as a drug carrier, nanoemulsions themselves have extensive antimicrobial 
activity against bacteria (e.g., E. coli, Salmonella, and S. aureus), viruses (e.g., HIV, Herpes 
simplex), fungi (e.g., Candida, Dermatophytes), protozoa and spores (e.g., anthrax) due to 
their ability to fuse with and lyse these different organisms. Fusion is primarily driven by the 
electrostatic attraction between the typically cationic charge of the emulsion and the anionic 
charge on the pathogen. There is one example of the antimicrobial effects of surfactant 
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nanoemulsions. A w/o nanoemulsion (X8W60PC), containing oil (64%), detergents (9.7%), 
solvent (8%) and water (18.3%), at a low concentration of 1%, significantly reduced the 
number of colony forming units (CFU) of Candida. albicans by more than four logs within 15 
minutes of treatment, and by six logs in a two-hour exposure. Because some of the ingredients 
of X8W60PC are biocidal, the anti-fungal activity of the individual ingredients was also 
evaluated at concentrations equivalent to those in X8W60PC. However, none of the 
constituents was as effective a fungicidal as the nanoemulsion (Figure 4), suggesting that the 
activity of X8W60PC depends upon its nanoemulsion structure [41].   
A special type of topical nanoemulsion has been developed for the instillation of an 
adrenergic β-blocking agent, adaprolol maleate, into the eye, to treat glaucoma without 
inducing systemic side-effects. However, the drug has an important clinical disadvantage of 
irritation to the eye, causing an immediate burning sensation and local discomfort. A 
nanoemulsion formulation, on the other hand, maintains the therapeutic efficacy of the drug 
while reducing the level of ocular irritation [32].  
3.3 Applications of nanoemulsions in cosmetics 
Nanoemulsions can be found in a wide variety of cosmetic products such as bath oils, body 
creams, anti-wrinkle and anti-aging preparations. Due to their small and uniform droplet size, 
nanoemulsions are transparent, fluid and pleasant to touch [42, 43]. In comparison to 
traditional emulsions, nanoemulsions have better spreading properties on the skin. These 
unique texture and rheological properties make them very valuable in cosmetic technology. 
Formulations containing nanoemulsions range from water-like fluids to semi-solid gels.  
Numerous patents reflect the active development of nanoemulsion formulations. For 
example, nanoemulsions containing fluid, non-ionic, amphiphilic lipids, such as diglyceryl 
isostearate, sorbitan oleate, and α-butylglucoside caprate, were stable on storage between 0°C 
and 45°C [44], were able to contain significant amounts of fragrance, and promoted the 
penetration of “actives” into the surface layers of the skin. Nanoemulsions made with anionic, 
amphiphilic lipids of phosphoric acid fatty esters and oxyethylenated derivatives also retained 
transparency and good cosmetic properties even when large amounts of oil were added to the 
formulations [45]. Another o/w nanoemulsion based on one or more nonionic and/or anionic 
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amphiphilic lipids, and one or more water-soluble neutral polymers (e.g. poly-(ethylene 
oxide), polyvinyl alcohols; polyvinylcaprolactam), allowed the viscosity of the composition 
to be increased without influencing its transparency or increasing the level of the oil phase 
[46]. A stable and translucent nanoemulsion for cosmetic, dermatological and/or 
ophthalmological applications comprised a ternary surfactant system of ethoxylated fatty ester 
polymer, fatty acid ester of sorbitan and alkali metal salts of cetyl phosphate or palmitoyl 
sarcosinate, did not require gelling agents for stabilization [47], making it suitable for use on 
sensitive skin. Several other nanoemulsion technologies have been developed for diverse 
properties, including sun-protection, anti-wrinkling, anti-aging of the skin and other cosmetic 
targets [48-52]. 
3.4 Summary 
Nanoemulsions consist of fine o/w or w/o dispersions. They are used in dermatology to 
improve drug delivery to and through the stratum corneum. In addition, nanoemulsions 
themselves are biocidal towards bacteria, viruses, fungi, protozoa and spores. In cosmetics, 
nanoemulsions have found use in many cosmetic products for their transparent visual aspect, 
hydrating power and good skin feel.  
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4 Liposomes 
4.1 Composition and preparation 
Liposomes are spherical vesicles consisting of one or more membrane-like phospholipid 
bilayers enclosing an aqueous core. Vesicle diameter ranges from fifty to several hundred 
nanometers. The principal lipid component of liposomes is typically phosphatidylcholine (PC) 
derived from egg or soybean lecithin [53]. Cholesterol is usually included in the composition 
to stabilize the structure thereby generating more rigid liposomes [54]. Depending on the 
processing conditions and the chemical composition, small unilamellar vesicles (SUV), large 
unilamellar vesicles (LUV), large multilamellar vesicles (MLV) and multivesicular vesicles 
(MVV) may be formed with one or several concentric bilayers (Figure 5). Unlike emulsions, 
liposomes are thermodynamically stable lamellar structures which form spontaneously when 
lipid is brought into contact with an aqueous phase [55].   
Liposomes can be prepared by a number of methods. The major techniques are lipid film 
hydration, emulsification, reverse phase evaporation, freeze-thaw processes, and solvent 
injection. Large liposomes form spontaneously when phospholipids are dispersed in water 
above their phase transition temperature. To prepare small vesicles, an appropriate technique, 
such as high-pressure homogenization, sonication, or extrusion, is required to reduce particle 
size. It should be stated that most of the methods for preparing liposomes have at least one of 
the following drawbacks: use of large quantities of solvent, need for special equipment, and 
low “active” encapsulation efficacy.  
Due to their biphasic character, liposomes can act as carriers for lipophilic, amphiphilic 
and hydrophilic substances. The entrapped compound’s solubility and partitioning 
characteristics will determine its location in the liposomal bilayer, its level of association with 
the liposome and its release rate. In general, lipophilic and amphiphilic substances, e.g., 
oil-soluble UV filters, are located in the lipid bilayer of the liposome. As such compounds are 
very poorly water-soluble, loss of entrapped drug on storage is minimal. Hydrophilic drugs 
are entrapped inside the aqueous core of liposomes, but may also be in the external water 
phase. The percentage of encapsulated hydrophilic drug depends on the liposome bilayer 
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composition and the preparation procedure.  
4.2 Applications of liposomes in pharmaceutics 
The first report of the use of liposomes in topical drug delivery involved delivery of 
triamcinolone acetonide. It was claimed that the liposomal formulation significantly increased 
the concentration of steroid achieved in the epidermis and dermis [56]. In a further study, it 
was reported that application of triamcinolone acetonide-loaded liposomes resulted in ~5-fold 
more drug accumulation within the epidermis in comparison to a more conventional gel 
formulation [57]. A number of other studies have implied the efficiency of liposome 
formulations to deliver enhanced drug amounts to the upper skin layers. For example, a 
liposome formulation of betamethasone dipropionate out-performed a commercial 
conventional formulation containing a higher concentration of drug in a clinical trial 
considering the treatment of atopic eczema [58]. The liposome formulation was less efficient 
in treating psoriasis for which deeper penetration of the drug is needed. Econazole, topical 
antifungal drug, can be irritant to the skin when topically applied in conventional vehicles. 
The application of liposome formulation has been shown to be a good strategy to minimize 
this irritation and enhance patient compliance. In biodisposition studies with a econazole in a 
liposomal gel dosage form, an ~7-fold increase in drug concentration in the epidermis was 
achieved, relative to a control cream [59]. It was possible, therefore, to reduce the applied 
drug dose yet maintain an equivalent therapeutic efficacy, thereby minimizing skin irritation. 
Similar results have been obtained with minoxidil, a drug to combat hair loss, and several 
liposomal products have been shown to be more efficient in delivering the drug to hair 
follicles than conventional dosage forms [59, 60]. Likewise, the local anesthetic agents, 
tetracaine and lidocaine, showed enhanced activity over conventional dermatological 
preparations when liposomal products were used [61, 62]. 
Of course, the efficiency of topical drug delivery from liposomal vehicles depends on the 
physicochemical properties of drug involved [63]. For example, the release of progesterone 
from Intralipid® emulsion was substantial, whereas egg-phosphatidylcholine and 
dipalmitoylphosphatidylcholine liposomal formulations delivered only 1% of the drug 
“payload” over a similar period [64]. The release of progesterone from liposomes followed 
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zero-order kinetics, controlled by slow interfacial transport of the drug from the bilayer into 
the surrounding aqueous medium.  
When caffeine (3% w/v) was delivered from (i) an aqueous solution, (ii) a PEG solution, 
(iii) an aqueous solution containing the enhancers, transcutol and oleic acid, (iv) a PEG-water 
solution with the same enhancers, and (v) a phosphatidylcholine/cholesterol liposomal (SV) 
formulation, the results in Figure 6 were obtained [65]. Notably, the enhancers were effective, 
and interestingly the vesicles significantly retarded the delivery of caffeine. This resulted, 
after 24 hours, in a much higher retention of the active in the epidermis following SV 
application. The same improved accumulation of drug in the skin has also been reported for a 
liposome formulation containing unfractionated heparin [66].  
The exact manner in which topical liposomes interact with the SC, and the lipids therein, is 
not fully characterized, especially when this occurs in the presence of an organic solvent, such 
as ethanol. Enhanced mixing with the intercellular lipids of the SC and/or the sebaceous lipid 
on the surface and within the hair follicles seems likely and logical. Microscopic observations 
have confirmed the fusion of liposomes on the SC surface resulting in stacks of lamellae and 
other, irregular structures [67]. It must be also remembered that the amount of lipid in the SC 
intercellular spaces may be small, relative to that applied in the form of liposomes. A square 
centimeter of SC of thickness of 10 µm has a volume of 1µl; given the “brick-and-mortar” 
structure of the SC, ~20% may be assumed to be associated with intercellular (and surface) 
lipid, which is 0.2 µl of lipid. Taking lipid density as about 1 g/ml (1 mg/µl), then the lipid 
content of 1 cm2 of SC is approximately 0.2 mg, an amount comparable to or smaller than the 
levels of lipid typically used when assessing the impact of formulations. It is perhaps not 
surprising, therefore, that enhanced deposition of drug into the SC is found when these 
preparations are used.  
4.3 Applications of liposomes in cosmetics 
Liposomes are found in numerous products designed to deliver active cosmetic substances 
into the epidermis. The aim is to concentrate the active ingredients in the outermost skin 
layers. For example, liposome-encapsulated UV filters incorporated into aqueous-based 
sunscreens products have good substantivity on the skin surface, thereby preventing them 
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from being easily washed off. Liposomes themselves, when formulated into cosmetics, can 
replenish/augment the endogenous SC lipids, increase moisturization and reduce skin dryness 
[68].  
There are many marketed liposomal cosmetics. Capture® was the first product 
incorporating liposomes and was introduced by C. Dior in 1986. It contains 5% thymus 
extract, 1% collagen and elastin peptides, and 0.1% hyaluronic acid in liposomes (100 nm 
diameter) made from soya lecithin [69]. Estée Lauder’s “Advanced Night Repair Protective 
Recovery Complex®” contains a liposome delivery system which is claimed to neutralize and 
repair 90% the damage caused by free radicals generated by UV, pollutants and oxidants. The 
formulation contains hyaluronic acid and is an effective moisturizer too. L'Oréal has 
pioneered the development of nanosomes (i.e., very small liposomes) in an anti-wrinkle 
product, “Revitalift® Double Lifting”, containing pro-retinol A [70]. Jafra Cosmetics 
International’s “Royal Jelly Lift Concentrate®” includes liposomes and a complex mixture of 
amino acids, vitamins and minerals, to stimulate cell renewal and prevent wrinkles [71]. 
Overall, cosmetic preparations containing liposomes range from simple creams and gels to 
complex formulations containing various extracts, moisturizers, antibiotics, and recombinant 
proteins for wound or sunburn healing. The commercial products are available as anti-aging 
skin creams, sunscreens, long-lasting perfumes, hair conditioners and so on.  
4.4 Summary 
The use of liposomes for the topical delivery of drugs and cosmetic actives represents a 
huge area of activity. The lipids comprising the vesicles clearly mix with endogenous SC 
lipids and transfer their encapsulated “payload” into the skin, sometimes undermining barrier 
function, at others providing reinforcement and improving hydration. Retention of an active at 
the SC surface can also be achieved as a positive benefit (e.g., for a sunscreen). Many 
cosmetic products based on liposomes have reached the market.  
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5 Transfersomes 
5.1 Composition and characteristics 
Transfersomes® (IDEA AG), are highly deformable mixed lipid aggregates, regarded as 
“elastic liposomes”. They differ from liposomes because of the presence of so-called 
edge-activators [72], and comprise phospholipids as the main ingredient with 10-25% 
surfactant (e.g. sodium cholate) and 3-10% ethanol. The surfactants are the “edge activators”, 
which confer ultradeformability on the transfersomes [73]. The elasticity of the vesicle is 
correlated with the quantity and the structure of the incorporated surfactant [74]. In 
comparison with liposomes, it has been claimed that transfersomes are able to deliver their 
“payload” deeper into the skin [58, 75].  
5.2 Interaction of transfersomes with the skin 
The proposed driving force for the putative penetration of transfersomes across the skin is 
the water activity gradient between the relatively dehydrated skin surface and the aqueous 
viable epidermis [76]. Hence, when a transfersome formulation is applied on the skin under 
non-occlusive conditions, the evaporation of water from the vehicle drives the penetration of 
vesicles towards the viable epidermis to avoid their dehydration [77]. It has been reported that 
transfersomes penetrate into the SC via two different hydrophilic pathways [78, 79]: (i) An 
intercluster route via the “gorge” between corneocytes clusters (formed by 3 to 10 individual 
corneocytes) which has a uniform width (≤ 4-6 µm) and depth (≤ 3-5 µm) (Figure 7); this 
pathway has a relatively low penetration resistance and corresponds to ≤ 1% of the total skin 
surface area. (ii) The intercorneocyte pathway travels between the individual corneocytes in 
the cell clusters, and occupies an area greater than 3% of the total skin surface area. 
5.3 Applications of transfersomes in pharmaceutics 
The anti-inflammatory action of topical triamcinolone acetonide delivered from 
transfersomes was significantly greater than that induced by marketed products [80]. 
Moreover, the biological activity of the drug was maintained at doses at least one order of 
magnitude lower than that commonly used in commercial topical lotions or creams. As a 
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result, it may be anticipated that any systemic side effects would be greatly reduced.  
It has also been reported that diclofenac associated with ultradeformable transfersomes is a 
good alternative for the combined oral and topical administration of the drug for rheumatoid 
disease [81]. Delivery from transfersomes sustained a prolonged therapeutic effect and 
resulted in a higher drug concentration in the skin than that from a commercial hydrogel. 
The topical administration of oestradiol from transfersomes and from rigid liposomes has 
been compared [82], and the deformable vesicles were shown to be significantly superior. 
This enhanced delivery was maintained for different “edge activators” [83]. Similarly, 
phosphatidylcholine vesicles containing sodium cholate, Span-80 or oleic acid significantly 
enhanced oestradiol transport across human skin in vitro relative to control formulations in 
which the transfersome constituents were present, but had not been assembled into the 
ultradeformable particles [84]. Similarly, flexible liposomes containing cyclosporin A 
delivered more drug into the skin than conventional vesicles [85].  
Finally, and remarkably, transfersomes have also been claimed as a technology for the 
non-invasive delivery of insulin across the skin [86, 87], although the ultimate practicality of 
the approach remains to be established.  
5.4 Summary 
Transfersomes have been claimed to enhance significantly the local and systemic delivery 
of a wide range of compounds. The osmotic gradient across nonoccluded skin has been 
proposed as the driving force for this improved delivery when ultradeformable vesicles are 
used. Initial applications are focused upon non-steroidal anti-inflammatory drugs with a site 
of action beneath the skin in the subcutaneous tissue.   
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6 Polymeric nanoparticles  
6.1 Nanocapsules 
6.1.1 Composition and preparation 
Polymeric nanocapsules are submicron colloidal particles with a core surrounded by a 
polymeric shell. In general, the core of nanocapsules is an organic (oil) solvent. Some of the 
most widely used polymers for the nanocapsule shell are poly-(ε-caprolactone) (PCL) [88], 
poly-L-lactide (PLA) [89], poly-(glycolic acid) (PGA), poly-(lactide-co-glycolide) (PLGA) 
[90], poly-(butylcyanoacrylates) [91-94], poly-(ethylcyanoacrylates) [95], poly-(alkylene 
adipate) [96], polyvinyl acetate (PVA) [97], cellulose acetate phthalate [98], 
poly-(ε-caprolactone)-block-poly-(ethylene glycol) [99], poly-(methyl methacrylate) [93], and 
polystyrene.   
Methods for preparing nanocapsules can be classified into two categories. The first 
involves in situ interfacial polymerization around a droplet [100]; the second requires 
interfacial nanodeposition of a preformed polymers [101]. In interfacial polymerization, either 
a monomer, or an amphiphilic polymer with a cross-linkable group, is used and 
polymerization is induced at the surface of a droplet. A w/o or o/w emulsion is usually formed 
first before the shell is polymerized at the interface of two phases [102, 103]. This technique 
allows the polymeric shell to follow the contour of the inner phase. The drawback is that the 
polymerization process may provoke side-reactions involving the drug or active ingredient 
and reduce thereby their ultimate availability from the formulation. In preparing nanocapsules 
from preformed polymers, the deposition of the polymer at the surface of an oil droplet can be 
achieved by mixing the organic phase containing the polymer with an aqueous phase 
containing a hydrophilic surfactant. As the nanometer-sized droplets of oil form, the polymer 
precipitates at the interface with the aqueous phase and the nanocapsules are stabilized by the 
surfactant [104]. This technique avoids some of drawbacks of the interfacial polymerization 
process, such as lack of control of molecular weight, the presence of residual monomer in the 
preparation, and the possibility of side-reactions.  
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6.1.2 Applications of nanocapsules 
Nanocapsules have been proposed as topical formulation constituents for several active 
compounds, including diclofenac, lidocaine, caffeine, retinoids, vitamin E, beta-carotene, 
amino acids, plant extracts, fragrances, antioxidants and UV protectants. The nanocapsule 
core has the advantage of providing a high loading capacity, with a relatively low polymer 
content. Compared to liposomes, polymeric nanocapsules are more robust as the shell is a 
covalently linked structure.  
6.1.2.1 Applications of nanocapsules in pharmaceutics 
The first polymeric particle system used for transdermal drug delivery comprised PLA 
microcapsules containing the contraceptive steroid, levonorgestrel [89]. Subsequently, 
indomethacin was encapsulated in poly-n-butylcyanoacrylate nanocapsules and improved the 
transdermal delivery of the drug compared with a conventional gel [94]. Nanoencapsulation 
of flufenamic acid using PLGA nanocapsules also resulted in significantly increased drug 
accumulation in the viable skin layers when assessed in vitro using different experimental 
models [90]. Delivery of chlorhexidine from PCL nanocapsules synthesized by interfacial 
polymerization has been assessed on eight bacteria strains. Sustained drug release was 
achieved and a prolonged ex vivo topical antimicrobial activity on porcine ear skin against 
Staphylococcus epidermis was reported [105]. The improved efficacy was explained by a 
more direct and sustained contact between the particles, bacteria, skin surface and hair 
follicles. 
6.1.2.2 Applications of nanocapsules in cosmetics 
Generally, nanocapsules are used in cosmetics to protect sensitive actives, reduce 
undesirable odours and avoid incompatibility between formulation ingredients. One of the 
first nanocapsule-based products was an anti-wrinkle cream encapsulating vitamin A; the 
particles acted as reservoirs, slowly releasing the active over time [106]. Recently, L'Oréal 
marketed two products, Primordiale Intense and Hydra Zen Serum, which use nanocapsules 
to encapsulate several active ingredients.  
Nanocapsules have also been intensively investigated as sunscreen vehicles for octyl 
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methoxycinnamate (OMC), octyl salicylate and benzophenone-3. It is believed that the 
nanocapsules form a protective film on the skin surface and retard any penetration of the 
active sunscreen into the viable tissue. For example, PCL has been used to prepare 
OMC-loaded nanocapsules which were more effective in protecting against UVB radiation 
than a conventional gel [88]. OMC was also encapsulated in cellulose acetate phthalate 
nanocapsules and its accumulation in the SC was compared to that from a nanoemulsion [98]. 
In this case, the nanocapsules were less efficient in delivering OMC. The encapsulation of 
benzophenone-3 (oxybenzone) in a series of nanoparticles made from PVA-fatty acid (Figure 
8) with different molecular weights has been reported [97]. The nanocapsules significantly 
decreased the transport of oxybenzone through porcine ear skin in vitro by more than an order 
of magnitude (Figure 9)   
6.2 Nanospheres  
Nanospheres comprise a homogeneous matrix of polymer in which the drug or active 
ingredient is dispersed throughout. Generally, methods used to prepare nanospheres can also 
be adapted to the manufacture of nanospheres [100], i.e., interfacial polymerization, emulsion 
polymerization and solvent evaporation [30].   
For example, the controlled release of captopril from poly-butylcyanoacrylate 
nanoparticles has been achieved, but improved skin transport was not observed [92]. 
Somewhat improved delivery of minoxidil from poly-(caprolactone)-block-poly-(ethylene 
glycol) nanoparticles was reported, with a better result achieved from that of smaller diameter 
(40 versus 130 nm) [99]. Further, cyclosporine A loaded into chitosan nanospheres better 
maintained an effective drug concentration on the ocular surface (for up to 48 hours) while 
avoiding systemic exposure, rapid clearance, eye irritation and blurred version [107]. 
6.3 Summary  
Polymeric nanoparticles are unable to cross intact SC. Drugs incorporated into 
nanoparticles may be slowly released onto the skin surface and into the superficial skin strata. 
Nanoparticles incorporated in cosmetic preparations can protect unstable active ingredients, 
avoid incompatibility between different ingredients, and ensure that the absorption of 
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sunscreens, for example, is avoided by forming a film on the skin surface. However, the 
number of products on the market that are based on polymeric nanoparticles is limited. This is 
due to a number of factors including the cytotoxicity of some polymers, and problems of 
scaling up the complex preparation methods involved.  
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7 Solid lipid nanoparticles (SLN) 
7.1 Composition and preparation 
SLN are sub-micrometer in size [108, 109]. The lipids employed include triglycerides, 
partial glycerides, fatty acids, steroids and wax. Different emulsifiers have been utilized to 
stabilize SLN dispersions, including Poloxamer 188, Polysorbate 80, lecithin, polyglycerol 
methylglucose distearate, sodium cocoamphoacetate and saccharose fatty acid esters [110].  
The two principal SLN preparation methods are high pressure homogenization and via 
microemulsion formation. The former is subdivided into hot and cold techniques [109, 
111-114]. Hot homogenization is the most frequently used. In this method, the lipid melt is 
dispersed in a hot surfactant solution at the same temperature by high-speed stirring. The 
resulting pre-emulsion is passed through a high pressure homogenizer to produce a hot o/w 
nanoemulsion. The lipid recrystallizes to SLN as the hot nanoemulsion is cooled to room 
temperature. It is noteworthy that for lipids (e.g., glycerides) with a low melting point close to 
room temperature, the nanoemulsion needs to be cooled to even lower temperatures to initiate 
recrystallization. The hot homogenization method may be suitable for temperature-sensitive 
compounds, because the time of exposure to an elevated temperature is relatively short [109].  
The cold homogenization technique is recommended for preparing SLN containing either 
highly temperature-sensitive compounds or hydrophilic compounds which can partition from 
the melted lipid phase to the water during a hot homogenization process [111]. In the cold 
homogenization technique, the melted lipid containing the drug is cooled, and then ground to 
microparticles which are subsequently dissolved in a cold surfactant solution to form a 
pre-emulsion. This is then homogenized into SLN at or below room temperature. As 
homogenization can cause an increase in temperature, the difference between the lipid 
melting point and the homogenization temperature should be large enough to avoid melting of 
lipid in the homogenizer.  
When SLN are produced by the microemulsion technique, the melted lipid and the aqueous 
surfactant solution must be at the same temperature. Surfactants and co-surfactants used 
include lecithin, bile salts and alcohols such as butanol. The two phases are mixed in the 
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correct ratio to form a microemulsion, which is then dispersed in a cold aqueous medium 
(2-3°C) under gentle mechanical mixing, to ensure that small particles are formed by 
precipitation [115].  
SLN can be also produced by a precipitation method [116]. The lipid is dissolved in an 
organic solvent and an aqueous phase is added provoking emulsification [117]. The solvent is 
then evaporated and the lipid precipitates forming nanoparticles. A disadvantage of this 
method is the use of organic solvent.  
7.2 Applications of SLN in pharmaceutics 
SLN have been used to enhance the topical delivery of several drugs. For example, SLN 
containing tristearin glyceride, soybean lecithin and polyethylene glycol 400 stearate 
increased the transport of triptolide in vitro by 3 to 4-fold over that from a simple solution of 
the drug [118]. In eczema patients, SLN loaded with clobetasol propionate showed improved 
efficacy over a conventional cream [119]. Prednicarbate associated with SLN (again for 
eczema treatment) was better delivered to the viable epidermis, with less exposure to (and 
atrophy of) the underlying dermis [113, 120], suggesting a possible targeting effect. 
Antiandrogens for acne treatment have also been shown to have better efficacy when topically 
applied in SLN formulations [121]. Once again, drug was concentrated in the outer skin layer 
and deeper penetration to underlying tissues and to the systemic circulation would be 
expected to be minimal. It was also shown that the lipophilic fluorescent marker, Nile Red, 
was delivered from the SLN to the hair follicle infundibulum, once more implying an ability 
to target a specific skin structure.  
7.3 Applications of SLN in cosmetics 
After topical application, SLN can form an occlusive adhesive film on the skin surface 
[122-126]. For example, an SLN formulation containing tocopherol acetate was twice as occlusive 
as an emulsion with identical lipid content (Figure 10) [123]. Scanning electron microscopy was 
used to visualize the SLN on a single tape, and showed complete film formation without 
distinguishing individual particles (Figure 11).  
SLN appear quite attractive as components for sunscreen products. Not only does the lipid 
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matrix at the skin surface retard the penetration of the active, molecular UV absorbers 
themselves (thereby reducing potential toxicity relative to conventional formulations) [111, 
123, 127-130], the SLN on their own have a sun-protective effect by efficiently scattering the 
radiation falling on the skin (similar to titanium dioxide particles [131]). Cetyl palmitate SLN 
containing molecular sunscreens have been shown to have this synergistic photoprotection 
effect [111, 123, 128, 131].  
Moreover, incorporation of chemically labile active ingredients (e.g., coenzyme Q10, 
retinol, and tocopherol) into SLN offers protection against decomposition [132-137] and, 
finally, it should be mentioned that the controlled release of an active ingredient is possible 
from SLN either to provide a burst release or a more sustained delivery profile [127]. This 
feature has been exploited for the controlled release of retinol and oxybenzone from SLN 
incorporated into creams and hydrogels [128, 135].   
7.4 Summary 
SLN have formed a wide range of applications and have useful properties for maintaining 
“actives” on the SC surface or within the upper skin layers. Their ability to form adhesive, 
occlusive films is particularly useful for sunscreen applications and for maintaining the 
stability of labile chemicals. 
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8 Ethosomes 
8.1 Composition and characteristics  
Ethosome are primarily composed of phospholipids, relatively high concentrations of 
ethanol, and water [138-141]. Their average diameter ranges from tens of nanometers to 
microns, and depends upon the relative amounts of phospholipids and ethanol [138]. Similar 
to liposomes, ethosomes can be unilamellar [142, 143] or multilamellar [138, 139, 144].  
A number of methods have been used to prepare stable ethosomal formulations depending 
on the drug characteristics and on the drug delivery target [140, 141]. The manufacturing 
processes are easily scaled-up. The presence of ethanol allows for efficient entrapment of 
hydrophilic, lipophilic and amphiphilic molecules. This feature is illustrated by research in 
which three fluorescent probes of distinct physicochemical properties were encapsulated in 
ethosomes and liposomes, and their behaviour was then examined by laser scanning confocal 
microscopy (LSCM) [138]. The three dyes were the lipophilic Rhodamine Red, 
dihexadecanoyl glycerophosphoethanolamine (RR), the amphiphilic 4-(4-diethylamino) 
styryl-N-methylpyridinium iodide (D-289), and the hydrophilic calcein. Figure 12 shows that 
the lipophilic and amphiphilic drugs were clearly associated with the liposomal bilayer, while 
calcein was concentrated in the aqueous core. In contrast, all the dyes were found throughout 
the entire volume of the ethosomes at high apparent loading.  
8.2 Enhanced transdermal drug delivery from ethosomes  
It is claimed that ethosomes significantly enhance drug delivery across the skin by two 
principal mechanisms: (a) a fluidizing effect of ethanol on phospholipid bilayers creating a 
“soft”, deformable vesicle [138, 142-144], and (b) SC lipid disruption by ethanol thereby 
permitting entry of ethosomes and their associated “payload” into the deeper skin layers 
(Figure 13) [138].  
Delivery of the three aforementioned fluorescent probes into nude mouse skin from 
ethosomes, liposomes and a hydroalcoholic solution was assessed by LSCM. For both 
rhodamine red and D-289, optical sectioning of the skin after an 8-hour application clearly 
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demonstrated that ethosomes were the superior delivery system (Figures 14 and 15). Uptake 
from the hydroalcoholic solution was greater than that from the liposomes employed. 
Quantitative analysis of the fluorescence intensity as a function of the depth again revealed 
the superiority of the ethosomal formulation, in this instance, for calcein and rhodamine red 
(Figure 16). 
Anti-infective drugs when associated with ethosomes appear to be much more efficient 
delivery systems than classic liposomes. For instance, fluorescently-labeled bacitracin, a 
polypeptide antibiotic, was delivered from ethosomes to a depth of 200 µm in dermatomed 
human cadaver skin, whereas its delivery from classic liposomes was negligible [144]. 
Another study with ethosomal erythromycin demonstrated an improved antibacterial action in 
comparison to a hydroethanolic solution of the drug. Moreover, an infected skin site treated 
with the topically applied ethosomal formulation healed as well as that achieved when the 
drug was systemically injected [145].  
Other examples of the efficacy of ethosomal vehicles can be mentioned. Pretreatment of 
the skin with a formulation containing ammonium glycyrrhizinate (AG), a natural 
anti-inflammatory agent effective in acute and chronic dermatitis, significantly reduced the 
intensity and duration of methyl nicotinate-induced erythema in healthy human volunteers, 
compared to hydroalcoholic solutions of the drug [146].  
Ethosomes have also been reported to enhance the percutaneous delivery of ionized drugs, 
very lipophilic compounds and large hydrophilic molecules. For example, the flux of 
trihexylphenidyl hydrochloride, an anti-Parkinsonian agent, from an ethosomal vehicle was 
substantially higher than that from liposomes [142]. Similar results have been reported for 
propranolol hydrochloride and sodium diclofenac [140]. Ethosomal formulations of 
testosterone have been compared with marketed transdermal patches, and shown to achieve 
significantly higher AUC and Cmax values [138, 147]. Finally, when acyclovir (an effective 
antiviral drug for the treatment of recurrent herpes labialis infection) was formulated in 
ethosomes, its delivery resulted in a marked improvement in therapeutic efficiency, compared 
to the normal treatment (Zovirax® cream), presumably as a result of the improved penetration 
of the active from the lipid-ethanol vehicle [148].   
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8.3 Summary 
Ethosomes have recorded some notable improvements in topical and transdermal drug 
delivery. While the precise mechanisms of action remain less than fully clear, the combination 
of a relatively high “dose” of exogenous lipid and ethanol appears to perturb SC barrier 
function. Whether this approach will ultimately make a significant impact in the clinic 
requires considerable further work.  
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9 Niosomes 
9.1 Composition and preparation 
Niosomes are vesicles prepared from non-ionic surfactants, such as polyoxyethylene alkyl 
ethers, sorbitan esters, polysorbate-cholesterol mixtures, crown ethers, perfluoroalkyl 
surfactants, alkyl glycerol ethers, and others [149-153]. The surfactants combine one or more 
hydrophobic components (e.g., alkyls (C12-C18) or perfluoroalkyls (C10) or a steroidal group) 
with a hydrophilic head group (e.g., ethylene oxide, glycerol, crown ether, polyhydroxyls, and 
sugars). The hydrophilic and hydrophobic moieties are linked by ether, ester, or amide bonds.  
Niosomes are prepared by similar methods to those used for liposomes, such as hydration 
of a deposited surfactant/lipid film. This process is usually followed by homogenization, 
sonication, or extrusion to reduce vesicle size, and then separation of the un-entrapped drug 
[149, 150, 152]. The stability of niosomal formulations is influenced by factors such as 
storage temperature, preparation technique, and composition [149, 152]. Vesicle aggregation 
may be prevented by co-formulation with surfactants. Like liposomes, niosomes can form 
unilamellar or multilamellar structures, and have the further advantages of improved stability, 
high purity and low cost.  
9.2 Interaction of niosomes with the skin 
The interactions of niosomes with the SC have been studied using microscopic techniques. 
The presence of vesicular structures on or near the surface are clearly seen, but this 
concentration is quickly attenuated as one examines (e.g., with sequential tape-stripping) the 
deeper SC layer [29]. The implication is that the niosomes have fused and mixed with the 
endogenous SC lipids at this point [154, 155]. Although some images of vesicular structures 
at even deeper regions of the SC have been published, it is impossible to say whether these 
really represent intact niosomes which have transported down from the skin surface, or 
whether there has been spontaneous regeneration of a vesicle as the degree of hydration of the 
SC increases.    
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9.3 Applications of niosomes in pharmaceutics and cosmetics 
Drugs encapsulated in niosomes, when these vesicles fuse with the SC, may be subjected 
to enhanced skin penetration due to an altered thermodynamic activity gradient [154, 155], or 
to the action of the “released” nonionic surfactants on SC barrier function [155, 156]. 
Enoxacin, for example, was much better delivered from niosomes than either liposomes or 
when applied as a simple drug solution [154]. If niosomes are used on skin for which the 
barrier function is significantly less than that typical of intact skin, then even rather large 
compounds can be delivered. Thus, β-galactosidase and luciferase reporter genes have been 
successfully transported across rat pup skin from niosome formulations [157]. In addition, 
and similar to other vesicular carriers, niosomes have been shown capable of drug delivery to 
hair follicles, with successful results reported for the polypeptides, interferon-α and 
cyclosporine [158], as well as for minoxidil [14]. From a transdermal standpoint, estradiol has 
been examined and the nature of the surfactant used to prepare the niosomes clearly has an 
important effect [159, 160]. Finally, niosomes have been incorporated into cosmetics for 
several years, and used in a manner not particularly different from liposomes [161].  
9.4 Summary 
 The behaviour and applications of niosomes parallel, in large part, those described for 
liposomes, although the level of activity, overall, is rather less.  
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10 Conclusions 
Research into nano-sized delivery systems for topical “actives” has been the focus of 
considerable effort in the pharmaceutical and cosmetic industries for more than twenty years. 
The composition of different nanoparticles and their methods of preparation show some 
diversity. However, a size-reduction step with high pressure homogenization, sonication or 
extrusion is usually required to break some sort of microemulsion into nanoparticles. 
Depending on their intended use, the resulting carriers can be designed to facilitate or to 
retard the penetration of drugs and active ingredients into the epidermis or deep dermis and 
beyond. Rigid nanoparticles, such as liposomes, polymeric nanocapsules and SLN, improve 
localization of the “active” in the upper skin layers, and may have an ability to form a skin 
surface film after topical application, thereby preventing water evaporation and increasing 
skin hydration. Transfersomes and ethosomes are variations of liposomes which incorporate 
“edge activators” or ethanol to confer the property of ultradeformability. It is claimed that this 
allows significantly enhanced transport of associated active species into the deeper skin layers 
via a variety of (not unambiguously proven) mechanisms, including an action as true 
“carriers”, SC lipid disruption, osmotic gradients, and so on.  
There is also a general perception that just about all nano-carriers can “target” appendagal 
structures, like hair follicles. However, it seems likely that this is a non-specific, physical 
phenomenon and it remains to be seen whether these observations can be translated into a real, 
observable benefit.  
In conclusion, despite a large and growing scientific and patent literature on the 
development and evaluation of nanoparticles for the delivery of topical agents, only a few 
commercial products containing such structures have appeared on the market. While the 
cosmetic industry has been quick to seize on these novel nanostructures, and to exploit their 
marketing and sensorial attributes, the pharmaceutical sector has been more reticent and has 
(currently) demanded quantifiable evidence that these inevitably more expensive products in 
terms of both materials and manufacture out-perform significantly more conventional 
formulations. For the moment, at least, this challenge has rarely been met.  
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Figure Legends 
Figure 1 Schematic representation of different kinds of nanoparticles.  
Figure 2 Skin permeation pathways. 
Figure 3 Image of a nanoemulsion (15% oil) stabilized with 0.2% carbomer at pH = 7.  
Figure 4 The susceptibility of Candida albicans to a X8W60PC nanoemulsion and to its 
individual ingredients. Cells were treated with either 0.1% X8W60PC 
nanoemulsion or with individual ingredients at the equivalent concentrations for 
15 minutes at 37°C. After treatment, cells were washed and plated on BH1 plates 
to assess the number of CFU. The bars represent standard error. D1, D2, and D3 
depict three detergents used to prepare X8W60PC.  
Figure 5 Schematic illustration of liposomes of different size and number of lamellae. 
Figure 6 Effect of different formulations on the flux of caffeine through hairless mouse 
skin (3% caffeine in each system). 
Figure 7 Left panel: laser scanning confocal microscopy image of nude mouse skin in vivo 
(~200 µm2 area). Right panel: Distribution of a fluorescent penetrant in the 
so-called intercluster (black) and intercorneocyte (grey) regions of the skin. 
Figure 8 Chemical structure of PVA-FA derivatives. 
Figure 9 Amount of benzophenone-3 absorbed across porcine ear skin in vitro (Mt), 
relative to the applied quantity (Mo), as a function of time following 
administration of various PVA-fatty acid nanocapsule-containing suspensions. 
The highest degree of transport occurred when the sunscreen was applied in 
solution in the absence of nanocapsules. 
Figure 10 Relative occlusivity of tocopherol acetate-based SLN and a reference emulsion 
after 6, 24 and 40 h post-application.  
Figure 11 Scanning electron micrograph of a dried SLN film on a single tape. 
Figure 12 Entrapment of three fluorescent probes by liposomes (a-c) and ethosomes (d-f). 
39 
The fluorescent probes were rhodamine red (a, d), D-289 (b, e) and calcein (e, f). 
White represents the highest concentration of probe, with yellow and red 
signifying progressively lower levels. 
Figure 13 Proposed mechanisms for enhanced drug delivery across the skin from ethosomal 
vehicles. 
Figure 14 LSCM images of rhodamine red penetration into nude mouse skin following an 8 
hour application of (a) ethosomes, (b) a hydroalcoholic solution of the dye, and (c) 
liposomes.  
Figure 15 LSCM images of D-289 penetration into nude mouse skin following an 8-hour 
application of (a) liposomes, (b) a hydroalcoholic solution of the dye, and (c) 
ethosomes. 
Figure 16 Skin penetration profiles of (A) calcein, and (B) rhodamine red, following their 
application to hairless mouse skin from either ethosomes, liposomes or a 
hydroethanolic solution for 8 hours. Depth of skin penetration and fluorescence 
intensity were determined by LSCM. Significantly different values (*p<0.001, 
**p<0.05; ethosomes versus other systems) are highlighted. 
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Figure 1: Schematic representation of (a) a nanoemulsion, (b) polymeric nanocapsules, (c) 
polymeric nanospheres, (d) individual liposomes, (e) an ethosome, (f) a transfersome, and (g) 
a niosome. 
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Figure 2: Skin permeation pathways. 
Stratum corneum 
Intercellular route Transcellular route Appendageal route 
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Figure 3: Image of a nanoemulsion (15% oil) stabilized with 0.2% carbomer at pH = 7. 
Adapted from reference [35].  
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Figure 4: The susceptibility of Candida albicans to a X8W60PC nanoemulsion and to its 
individual ingredients. Cells were treated with either 0.1% X8W60PC nanoemulsion or with 
individual ingredients at the equivalent concentrations for 15 minutes at 37°C. After treatment, 
cells were washed and plated on BH1 plates to assess the number of CFU. The bars represent 
standard error. D1, D2, and D3 depict three detergents used to prepare X8W60PC. Redrawn 
from reference [41].  
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Figure 5: Schematic illustration of liposomes of different size and number of lamellae. 
Redrawn from reference [33].  
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Figure 6: Effect of different formulations on the flux of caffeine through hairless mouse skin 
(3% caffeine in each system). Adapted from reference [65].  
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Figure 7: Left panel: laser scanning confocal microscopy image of nude mouse skin in vivo 
(~200 µm2 area). Right panel: Distribution of a fluorescent penetrant in the so-called 
intercluster (black) and intercorneocyte (grey) regions of the skin. Reprinted from reference 
[79]. 
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Figure 8: Chemical structure of PVA-FA derivatives. Redrawn from reference [97].  
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Figure 9: Amount of benzophenone-3 absorbed across porcine ear skin in vitro (Mt), relative 
to the applied quantity (Mo), as a function of time following administration of various 
PVA-fatty acid nanocapsule-containing suspensions. The highest degree of transport occurred 
when the sunscreen was applied in solution in the absence of nanocapsules. Redrawn from 
reference [97].  
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Figure 10: Relative occlusivity of tocopherol acetate-based SLN and a reference emulsion 
after 6, 24 and 40 h post-application. Redrawn from reference [123].  
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Figure 11: Scanning electron micrograph of a dried SLN film on a single tape. Reprinted 
from reference [123].  
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Figure 12: Entrapment of three fluorescent probes by liposomes (a-c) and ethosomes (d-f). 
The fluorescent probes were rhodamine red (a, d), D-289 (b, e) and calcein (e, f). White 
represents the highest concentration of probe, with yellow and red signifying progressively 
lower levels. Reprinted from reference [138].  
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Figure 13: Proposed mechanisms for enhanced drug delivery across the skin from ethosomal 
vehicles. Adapted from reference [138].
Intercellular pathway 
Stratum corneum Stratum corneum  
 lipids multilayers 
Ethanol 
Drug 
Ethosomes 
53 
   
 
Figure 14: LSCM images of rhodamine red penetration into nude mouse skin following an 8 hour application of (a) ethosomes, (b) a hydroalcoholic solution 
of the dye, and (c) liposomes. Reprinted from reference [138]. 
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Figure 15: LSCM images of D-289 penetration into nude mouse skin following an 8-hour application of (a) liposomes, (b) a hydroalcoholic solution of the 
dye, and (c) ethosomes. Reprinted from reference [142].
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(B) 
Figure 16: Skin penetration profiles of (A) calcein, and (B) rhodamine red, following their application 
to hairless mouse skin from either ethosomes, liposomes or a hydroethanolic solution for 8 hours. 
Depth of skin penetration and fluorescence intensity were determined by LSCM. Significantly 
different values (*p<0.001, **p<0.05; ethosomes versus other systems) are highlighted. Redrawn from 
reference [162].  
 
